CN1668293A - 使用青蒿素样化合物预防或延缓癌症显现的方法 - Google Patents

使用青蒿素样化合物预防或延缓癌症显现的方法 Download PDF

Info

Publication number
CN1668293A
CN1668293A CNA038167972A CN03816797A CN1668293A CN 1668293 A CN1668293 A CN 1668293A CN A038167972 A CNA038167972 A CN A038167972A CN 03816797 A CN03816797 A CN 03816797A CN 1668293 A CN1668293 A CN 1668293A
Authority
CN
China
Prior art keywords
free radical
iron
cancer
artemisinin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038167972A
Other languages
English (en)
Chinese (zh)
Inventor
H·C·莱
N·P·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN1668293A publication Critical patent/CN1668293A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CNA038167972A 2002-06-06 2003-06-06 使用青蒿素样化合物预防或延缓癌症显现的方法 Pending CN1668293A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38692802P 2002-06-06 2002-06-06
US60/386,928 2002-06-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010165713A Division CN101843904A (zh) 2002-06-06 2003-06-06 使用青蒿素样化合物预防或延缓癌症显现的方法

Publications (1)

Publication Number Publication Date
CN1668293A true CN1668293A (zh) 2005-09-14

Family

ID=29736235

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201010165713A Pending CN101843904A (zh) 2002-06-06 2003-06-06 使用青蒿素样化合物预防或延缓癌症显现的方法
CNA038167972A Pending CN1668293A (zh) 2002-06-06 2003-06-06 使用青蒿素样化合物预防或延缓癌症显现的方法
CNB038167956A Expired - Fee Related CN1313145C (zh) 2002-06-06 2003-06-06 青蒿素相关性内过氧化物与携带铁的蛋白质之间的共价缀合物及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201010165713A Pending CN101843904A (zh) 2002-06-06 2003-06-06 使用青蒿素样化合物预防或延缓癌症显现的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038167956A Expired - Fee Related CN1313145C (zh) 2002-06-06 2003-06-06 青蒿素相关性内过氧化物与携带铁的蛋白质之间的共价缀合物及其使用方法

Country Status (11)

Country Link
US (2) US20040058981A1 (enExample)
EP (2) EP1531851B1 (enExample)
JP (2) JP4440768B2 (enExample)
CN (3) CN101843904A (enExample)
AU (2) AU2003243418B2 (enExample)
BR (2) BR0312685A (enExample)
CA (2) CA2488360A1 (enExample)
NZ (2) NZ537114A (enExample)
RU (2) RU2325156C2 (enExample)
WO (1) WO2003103588A2 (enExample)
ZA (1) ZA200500023B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323569B (zh) * 2008-07-24 2011-01-26 上海交通大学 倍半萜青蒿萜酯ae及其提取纯化方法
CN102395362A (zh) * 2009-04-23 2012-03-28 伦敦制药有限公司 含二氢青蒿素的舌下喷雾制剂
CN102399142A (zh) * 2010-09-14 2012-04-04 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
WO2012136125A1 (zh) * 2011-04-08 2012-10-11 Shi Yanyu 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂
WO2014082570A1 (zh) * 2012-11-29 2014-06-05 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594491B1 (en) 2003-02-12 2010-10-20 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
BRPI0414017B8 (pt) * 2003-09-17 2021-05-25 Nektar Therapeutics Al Corp pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1255106C (zh) * 2003-09-26 2006-05-10 李国桥 复方青蒿素
US20050096369A1 (en) * 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
KR20060109915A (ko) * 2003-11-19 2006-10-23 벡타 리미티드 엔도퍼옥사이드 브리지 함유 화합물을 이용하여 헬리코박터파일로리 연관 질병의 치료를 위한 방법 및 조성물
CN1311832C (zh) * 2005-01-12 2007-04-25 四川科伦药业股份有限公司 溴代二氢青蒿素的医药用途
US20060270863A1 (en) * 2005-05-27 2006-11-30 Amyris Biotechnologies Conversion of amorpha-4,11-diene to artemisinin and artemisinin precursors
JP5119155B2 (ja) * 2005-10-20 2013-01-16 エピフアルマ・アクチエンゲゼルシヤフト アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US20070231300A1 (en) * 2006-03-28 2007-10-04 Washington, University Of Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
WO2008066902A2 (en) * 2006-11-30 2008-06-05 Nektar Therapeutics Al, Corporation Method for preparing a polymer conjugate
US7928095B2 (en) * 2007-02-09 2011-04-19 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
SG172737A1 (en) * 2008-01-30 2011-07-28 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinaseand methods for obtaining the same
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
EP2349346B1 (en) 2008-09-23 2019-08-28 Nektar Therapeutics Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
CN102215688A (zh) * 2008-10-21 2011-10-12 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
JP5624735B2 (ja) 2009-07-22 2014-11-12 国立大学法人岡山大学 フィルター
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN103405779B (zh) * 2013-07-18 2015-09-30 江苏省血吸虫病防治研究所 一种预防血吸虫感染长效青蒿琥酯药物及其制备方法
GB201800736D0 (en) 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN109908137B (zh) * 2019-03-11 2022-02-18 江苏省人民医院（南京医科大学第一附属医院） 青蒿素在杀伤乳腺癌干细胞的药物中的应用
CN114983999A (zh) * 2022-06-09 2022-09-02 四川大学 一种青蒿素及其衍生物的新用途、验证方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
RU2098407C1 (ru) * 1989-09-27 1997-12-10 Рон-Пуленк Рорер С.А. Способ получения пероксиацетальлактонового соединения (варианты) и лактон
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5472684A (en) * 1993-06-02 1995-12-05 Colgate Palmolive Company Oral compositions for plaque and gingivitis
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5677468A (en) * 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
US5869310A (en) * 1996-06-03 1999-02-09 Promega Corporation Isolated agarase enzyme from flavobacterium sp. strain NR19, cloned genes therefor, and expression thereof in transformed host cells
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
CN1084333C (zh) * 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
US6127405A (en) * 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
US6297272B1 (en) * 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
IN191696B (enExample) * 1999-02-12 2003-12-20 Council Scient Ind Res
GB9916012D0 (en) * 1999-07-09 1999-09-08 Ufc Limited Peroxide-based antimalarial compounds
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323569B (zh) * 2008-07-24 2011-01-26 上海交通大学 倍半萜青蒿萜酯ae及其提取纯化方法
CN102395362A (zh) * 2009-04-23 2012-03-28 伦敦制药有限公司 含二氢青蒿素的舌下喷雾制剂
CN102399142A (zh) * 2010-09-14 2012-04-04 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
CN102399142B (zh) * 2010-09-14 2014-09-24 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
WO2012136125A1 (zh) * 2011-04-08 2012-10-11 Shi Yanyu 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂
WO2014082570A1 (zh) * 2012-11-29 2014-06-05 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途
CN103845360A (zh) * 2012-11-29 2014-06-11 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途

Also Published As

Publication number Publication date
RU2004139090A (ru) 2005-06-10
ZA200500023B (en) 2005-10-20
RU2004139096A (ru) 2005-06-10
CN101843904A (zh) 2010-09-29
JP2005535606A (ja) 2005-11-24
RU2325156C2 (ru) 2008-05-27
EP1553935A2 (en) 2005-07-20
CA2488347A1 (en) 2003-12-18
NZ537114A (en) 2007-02-23
JP2005529938A (ja) 2005-10-06
EP1531851A2 (en) 2005-05-25
BR0311627A (pt) 2005-08-30
CN1668323A (zh) 2005-09-14
WO2003103588A3 (en) 2004-04-15
AU2003251405A1 (en) 2003-12-22
US20040058981A1 (en) 2004-03-25
CA2488360A1 (en) 2003-12-18
EP1531851B1 (en) 2011-12-14
JP4440768B2 (ja) 2010-03-24
EP1553935A4 (en) 2010-07-07
AU2003243418A1 (en) 2003-12-22
AU2003243418B2 (en) 2009-02-19
NZ537113A (en) 2007-01-26
US20080119542A1 (en) 2008-05-22
EP1531851A4 (en) 2007-12-12
WO2003103588A2 (en) 2003-12-18
CN1313145C (zh) 2007-05-02
BR0312685A (pt) 2005-09-06

Similar Documents

Publication Publication Date Title
CN1668293A (zh) 使用青蒿素样化合物预防或延缓癌症显现的方法
AU2007203159B2 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
EP4157251A1 (en) Methods of antipathogenic treatment
EP1007055A1 (en) Methods for the administration of amifostine
US7053072B2 (en) Methods for the administration of amifostine and related compounds
KR20160003652A (ko) 감마―글루타밀 주기 조절 방법 및 조성물
CN1140997A (zh) 用于治疗增殖性疾病、转移瘤和药物抗性肿瘤的钒酸盐化合物
EP1372677B1 (en) Use of compositions comprising sesquiterpene derivatives for the treatment of cancer
JP2002302447A (ja) 局所投与用癌治療剤
WO2024178621A1 (en) Use of compounds in preventing and/or treating obesity or nafld
CN101708184B (zh) 铁脂质体的药物应用
US20130029996A1 (en) Special composition for the use thereof as a drug
US20240358669A1 (en) Methods for treating pancreatic cancer
CA2407442A1 (fr) Nouveaux medicaments a base de melanges de sesquiterpenes
ZA200500027B (en) Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer.
WO2007091557A1 (ja) 肝癌治療又は予防用医薬組成物
HK40084623A (en) Use of glycerol phospholipids in the prevention and treatment of hyperlipidemia, atherosclerosis, non-alcoholic fatty liver and obesity
CN112656794A (zh) 吡咯喹啉醌或其盐在制备用于防治前列腺增生药物中的用途及药物组合物
Amin et al. EFFECT OF L-CARNITINE ON THE LINGUAL MUCOSA OF STREPTOZOTOCIN-INDUCED DIABETIC ALBINO RATS
CN101076354A (zh) 用于肠道给药的载体
HK1174555A1 (en) Medicine composition containing vitamin d3 and metformin
HK1174555B (zh) 含维生素d3和二甲双胍的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050914